Table of Content

1 INTRODUCTION (Page No. - 31)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
           1.3.3 CURRENCY CONSIDERED
    1.4 STAKEHOLDERS 
    1.5 SUMMARY OF CHANGES 
2 RESEARCH METHODOLOGY (Page No. - 35)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                    2.1.2.3 Breakdown of primary interviews: supply- and demand-side participants
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  AND REGION (SUPPLY SIDE)
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION,  AND REGION (DEMAND SIDE)
    2.2 MARKET SIZE ESTIMATION 
           2.2.1 BOTTOM-UP APPROACH
                    FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
                    FIGURE 5 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
                    FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 7 DATA TRIANGULATION
    2.4 MARKET SHARE ASSESSMENT 
    2.5 ASSUMPTIONS 
    2.6 RISK ASSESSMENT 
    2.7 RESEARCH LIMITATIONS 
           2.7.1 METHODOLOGY-RELATED LIMITATIONS
           2.7.2 SCOPE-RELATED LIMITATIONS
    2.8 IMPACT OF RECESSION ON NEUROMODULATION MARKET 
3 EXECUTIVE SUMMARY (Page No. - 47)
    FIGURE 8 NEUROMODULATION MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 9 NEUROMODULATION INDUSTRY FOR INTERNAL, BY TYPE,  2023 VS. 2028 (USD MILLION)
    FIGURE 10 MARKET FOR EXTERNAL, BY TYPE,  2023 VS. 2028 (USD MILLION)
    FIGURE 11 NEUROMODULATION INDUSTRY, BY REGION
4 PREMIUM INSIGHTS (Page No. - 50)
    4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN NEUROMODULATION MARKET 
          FIGURE 12 RISING PREVALENCE OF NEUROLOGICAL DISORDERS TO CREATE LUCRATIVE OPPORTUNITIES FOR MARKET PLAYERS
    4.2 NORTH AMERICAN NEUROMODULATION INDUSTRY, BY TYPE AND COUNTRY 
          FIGURE 13 INTERNAL NEUROMODULATION SEGMENT AND US ACCOUNTED FOR LARGEST SHARES OF NORTH AMERICAN MARKET IN 2022
    4.3 NEUROMODULATION MARKET, BY COUNTRY 
          FIGURE 14 CHINA TO REGISTER HIGHEST CAGR IN MARKET DURING FORECAST PERIOD
    4.4 NEUROMODULATION MARKET, BY REGION 
          FIGURE 15 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
    4.5 NEUROMODULATION MARKET: DEVELOPED VS. DEVELOPING MARKETS 
          FIGURE 16 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 54)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 17 NEUROMODULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,  CHALLENGES, AND TRENDS
           5.2.1 DRIVERS
                    5.2.1.1 Rising prevalence of neurological disorders and nerve injuries
                    5.2.1.2 Increasing focus on development of advanced neuromodulation and neurostimulation technologies
                    5.2.1.3 Increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices
                    5.2.1.4 Growing geriatric population and subsequent increase in prevalence of neurological disorders
                    5.2.1.5 Availability of reimbursements for neuromodulation devices
                    5.2.1.6 Government-led support for research on neurological disorders
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of neuromodulation procedures
                    5.2.2.2 Preference for drug therapies over neuromodulation products
                    5.2.2.3 Adverse effects and complications associated with neuromodulation devices
                                TABLE 1 POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH DIFFERENT NEUROMODULATION DEVICES
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Large population and increasing healthcare expenditure in emerging economies
                    5.2.3.2 Widening application scope of neuromodulation
                                TABLE 2 INDICATIVE LIST OF NEUROMODULATION CLINICAL TRIALS
                                FIGURE 18 PUBLISHED RESEARCH PAPERS, 2013–2022
           5.2.4 CHALLENGES
                    5.2.4.1 Stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices
                    5.2.4.2 Shortage of trained professionals
                    5.2.4.3 Product recalls
                                TABLE 3 MAJOR PRODUCT RECALLS
           5.2.5 TRENDS
                    5.2.5.1 Role of artificial intelligence (AI) in advancing neuromodulation
    5.3 VALUE CHAIN ANALYSIS 
          FIGURE 19 NEUROMODULATION INDUSTRY: VALUE CHAIN ANALYSIS
           5.3.1 RESEARCH AND DEVELOPMENT (R&D)
           5.3.2 MANUFACTURING AND ASSEMBLY
           5.3.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
    5.4 SUPPLY CHAIN ANALYSIS 
          FIGURE 20 DIRECT DISTRIBUTION—PREFERRED STRATEGY OF PROMINENT COMPANIES
    5.5 TECHNOLOGY ANALYSIS 
    5.6 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 4 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.6.1 THREAT OF NEW ENTRANTS
           5.6.2 INTENSITY OF COMPETITIVE RIVALRY
           5.6.3 BARGAINING POWER OF BUYERS
           5.6.4 BARGAINING POWER OF SUPPLIERS
           5.6.5 THREAT OF SUBSTITUTES
    5.7 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
                    TABLE 5 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS BY END USER
           5.7.2 BUYING CRITERIA
          FIGURE 22 KEY BUYING CRITERIA BY END USER
    5.8 REGULATORY LANDSCAPE 
          TABLE 6 LIST OF REGULATORY AUTHORITIES GOVERNING NEUROMODULATION
           5.8.1 REGULATORY LANDSCAPE, BY REGION
                    5.8.1.1 North America
                               5.8.1.1.1 US
                                              TABLE 7 CLASSIFICATION OF MEDICAL DEVICES BY US FDA
                    5.8.1.2 Europe
                    5.8.1.3 Asia Pacific
                               5.8.1.3.1 India
                               5.8.1.3.2 China
                                              TABLE 8 NMPA MEDICAL DEVICES CLASSIFICATION
                    5.8.1.4 Japan
                                TABLE 9 JAPAN: CLASSIFICATION OF MEDICAL DEVICES
    5.9 PATENT ANALYSIS 
    5.10 KEY CONFERENCES AND EVENTS, 2024–2025 
           TABLE 10 NEUROMODULATION MARKET: LIST OF CONFERENCES AND EVENTS, 2024–2025
    5.11 PRICING ANALYSIS 
           TABLE 11 PRICE RANGE OF NEUROMODULATION DEVICES AND PROCEDURES, 2022
    5.12 TRADE ANALYSIS 
           TABLE 12 IMPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY,  2018–2022 (USD MILLION)
           TABLE 13 EXPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY,  2018–2022 (USD MILLION)
    5.13 ECOSYSTEM MAPPING 
           FIGURE 23 NEUROMODULATION INDUSTRY: ECOSYSTEM MAPPING
           TABLE 14 COMPANIES AND THEIR ROLES IN NEUROMODULATION ECOSYSTEM
           FIGURE 24 KEY PLAYERS IN NEUROMODULATION MARKET
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           FIGURE 25 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
6 NEUROMODULATION MARKET, BY TYPE (Page No. - 75)
    6.1 INTRODUCTION 
          TABLE 15 NEUROMODULATION INDUSTRY, BY TYPE, 2021–2028 (USD MILLION)
    6.2 INTERNAL NEUROMODULATION 
          TABLE 16 INTERNAL: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 17 INTERNAL: NEUROMODULATION MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.1 SPINAL CORD STIMULATION
                    6.2.1.1 Growing incidence of spinal cord injuries to fuel market growth
                                TABLE 18 SPINAL CORD STIMULATION DEVICES OFFERED BY MAJOR COMPANIES
                                TABLE 19 INTERNAL: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY REGION, 2021–2028 (USD MILLION)
           6.2.2 DEEP BRAIN STIMULATION
                    6.2.2.1 Growing use to control debilitating symptoms caused by neurological disorders to drive market
                                TABLE 20 DEEP BRAIN STIMULATION DEVICES OFFERED BY MAJOR COMPANIES
                                TABLE 21 INTERNAL: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY REGION, 2021–2028 (USD MILLION)
           6.2.3 VAGUS NERVE STIMULATION
                    6.2.3.1 Rising geriatric population and high incidence of epilepsy to drive market
                                TABLE 22 VAGUS NERVE STIMULATION DEVICES OFFERED BY MAJOR COMPANIES
                                TABLE 23 INTERNAL: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY REGION, 2021–2028 (USD MILLION)
           6.2.4 SACRAL NERVE STIMULATION
                    6.2.4.1 Widening application scope of sacral nerve stimulation to drive market
                                TABLE 24 SACRAL NERVE STIMULATION DEVICES OFFERED BY MAJOR COMPANIES
                                TABLE 25 INTERNAL: MARKET FOR SACRAL NERVE STIMULATION, BY REGION, 2021–2028 (USD MILLION)
           6.2.5 GASTRIC ELECTRICAL STIMULATION
                    6.2.5.1 Growing number of people suffering from severe gastroesophageal reflux disease (GERD) and gastroparesis to fuel market growth
                                TABLE 26 GASTRIC ELECTRICAL STIMULATION DEVICES OFFERED BY MAJOR COMPANIES
                                TABLE 27 INTERNAL: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION,  BY REGION, 2021–2028 (USD MILLION)
    6.3 EXTERNAL NEUROMODULATION 
          TABLE 28 EXTERNAL NEUROMODULATION: NEUROMODULATION INDUSTRY, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 29 EXTERNAL NEUROMODULATION: NEUROMODULATION INDUSTRY, BY REGION,  2021–2028 (USD MILLION)
           6.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
                    6.3.1.1 Extensive use in healthcare sector, low cost, and ease of use to fuel market growth
                                TABLE 30 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION DEVICES OFFERED BY MAJOR COMPANIES
                                TABLE 31 EXTERNAL: NEUROMODULATION INDUSTRY FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2021–2028 (USD MILLION)
           6.3.2 TRANSCRANIAL MAGNETIC STIMULATION (TMS)
                    6.3.2.1 Minimal patient discomfort associated with transcranial magnetic stimulation (TMS) to support demand
                                TABLE 32 TRANSCRANIAL MAGNETIC STIMULATION DEVICE OFFERED BY MAJOR COMPANIES
                                TABLE 33 EXTERNAL: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY REGION, 2021–2028 (USD MILLION)
           6.3.3 RESPIRATORY ELECTRICAL STIMULATION
                    6.3.3.1 High treatment efficacy to fuel market growth
                                TABLE 34 RESPIRATORY ELECTRICAL STIMULATION DEVICE OFFERED BY MAJOR COMPANIES
                                TABLE 35 EXTERNAL: NEUROMODULATION INDUSTRY FOR RESPIRATORY ELECTRICAL STIMULATION, BY REGION, 2021–2028 (USD MILLION)
7 NEUROMODULATION MARKET, BY APPLICATION (Page No. - 90)
    7.1 INTRODUCTION 
    7.2 NEUROMODULATION INDUSTRY FOR SPINAL CORD STIMULATION, BY APPLICATION 
          TABLE 36 NEUROMODULATION INDUSTRY FOR SPINAL CORD STIMULATION, BY APPLICATION,  2021–2028 (USD MILLION)
           7.2.1 CHRONIC PAIN
                    7.2.1.1 High incidence of chronic pain to support market growth
                                TABLE 37 SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY REGION,  2021–2028 (USD MILLION)
           7.2.2 FAILED BACK SURGERY SYNDROME (FBSS)
                    7.2.2.1 Increasing incidence of failed back surgery syndrome (FBSS) with rising number of surgeries annually to drive demand
                                TABLE 38 SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME,  BY REGION, 2021–2028 (USD MILLION)
           7.2.3 ISCHEMIA
                    7.2.3.1 High effectiveness of neuromodulation for ischemia treatment to support market growth
                                TABLE 39 SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY REGION,  2021–2028 (USD MILLION)
    7.3 NEUROMODULATION INDUSTRY FOR DEEP BRAIN STIMULATION,  BY APPLICATION 
          TABLE 40 MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION,  2021–2028 (USD MILLION)
           7.3.1 PARKINSON’S DISEASE
                    7.3.1.1 Rising incidence of Parkinson’s disease and growing R&D for innovation to drive market
                                TABLE 41 DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY REGION,  2021–2028 (USD MILLION)
           7.3.2 TREMORS
                    7.3.2.1 High efficacy of deep brain stimulation (DBS) in treating tremors to boost demand
                                TABLE 42 DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY REGION,  2021–2028 (USD MILLION)
           7.3.3 DEPRESSION
                    7.3.3.1 Rising research and clinical studies related to depression treatment to drive market
                                TABLE 43 DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY REGION,  2021–2028 (USD MILLION)
           7.3.4 OTHER DBS APPLICATIONS
                    TABLE 44 DEEP BRAIN STIMULATION MARKET FOR OTHER DBS APPLICATIONS, BY REGION,  2021–2028 (USD MILLION)
    7.4 NEUROMODULATION INDUSTRY FOR SACRAL NERVE STIMULATION, BY APPLICATION 
          TABLE 45 MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
           7.4.1 URINE INCONTINENCE
                    7.4.1.1 High incidence of urine incontinence to create growth opportunities
                                TABLE 46 SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY REGION,  2021–2028 (USD MILLION)
           7.4.2 FECAL INCONTINENCE
                    7.4.2.1 Reduced symptom recurrence with use of SNS in fecal incontinence treatment to drive demand
                                TABLE 47 SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY REGION,  2021–2028 (USD MILLION)
    7.5 NEUROMODULATION INDUSTRY FOR VAGUS NERVE STIMULATION (VNS), BY APPLICATION 
          TABLE 48 MARKET FOR VAGUS NERVE SIMULATION, BY APPLICATION,  2021–2028 (USD MILLION)
           7.5.1 EPILEPSY
                    7.5.1.1 Advantages associated with VNS in epilepsy treatment to propel market growth
                                TABLE 49 VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY REGION,  2021–2028 (USD MILLION)
           7.5.2 OTHER VNS APPLICATIONS
                    TABLE 50 VAGUS NERVE STIMULATION MARKET FOR OTHER VNS APPLICATIONS, BY REGION,  2021–2028 (USD MILLION)
    7.6 NEUROMODULATION INDUSTRY FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION 
          TABLE 51 MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
           7.6.1 GASTROPARESIS
                    7.6.1.1 Reduced hospitalization time for patients affected by gastroparesis by GES treatment to drive market
                                TABLE 52 GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY REGION,  2021–2028 (USD MILLION)
           7.6.2 OBESITY
                    7.6.2.1 High prevalence of obesity and risks associated with gastric bypass to fuel demand
                                TABLE 53 GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY REGION,  2021–2028 (USD MILLION)
    7.7 NEUROMODULATION INDUSTRY FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION 
          TABLE 54 MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
           7.7.1 TREATMENT-RESISTANT DEPRESSION
                    7.7.1.1 Increasing prevalence of depression to boost market growth
                              TABLE 55 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY REGION, 2021–2028 (USD MILLION)
           7.7.2 OTHER TENS APPLICATIONS
                    TABLE 56 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR OTHER TENS APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
    7.8 NEUROMODULATION INDUSTRY FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION 
          TABLE 57 MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 58 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2021–2028 (USD MILLION)
           7.8.1 DEPRESSION
                    7.8.1.1 High effectiveness of TMS and increased acceptance among patients to drive market
                                TABLE 59 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION,  2021–2028 (USD MILLION)
           7.8.2 MIGRAINE
                    7.8.2.1 High prevalence of migraine to support market growth
                                TABLE 60 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY REGION,  2021–2028 (USD MILLION)
    7.9 NEUROMODULATION INDUSTRY FOR RESPIRATORY ELECTRICAL STIMULATION, BY APPLICATION 
           7.9.1 SPINAL CORD INJURY
                    7.9.1.1 Rising incidence of spinal cord injuries to fuel demand
                                TABLE 61 RESPIRATORY ELECTRICAL STIMULATION MARKET FOR SPINAL CORD INJURY, BY REGION, 2021–2028 (USD MILLION)
8 NEUROMODULATION MARKET, BY REGION (Page No. - 107)
    8.1 INTRODUCTION 
          TABLE 62 NEUROMODULATION INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
    8.2 NORTH AMERICA 
          FIGURE 26 NORTH AMERICA: NEUROMODULATION MARKET SNAPSHOT
          TABLE 63 NORTH AMERICA: MARKET, BY COUNTRY,  2021–2028 (USD MILLION)
          TABLE 64 NORTH AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 65 NORTH AMERICA: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 66 NORTH AMERICA: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 67 NORTH AMERICA: MARKET FOR SPINAL CORD STIMULATION,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 68 NORTH AMERICA: MARKET FOR DEEP BRAIN STIMULATION,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 69 NORTH AMERICA: MARKET FOR SACRAL NERVE STIMULATION,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 70 NORTH AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 71 NORTH AMERICA: MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 72 NORTH AMERICA: MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 73 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
           8.2.1 US
                    8.2.1.1 Large presence of prominent players to drive market
                                FIGURE 27 PROJECTED NUMBER OF PEOPLE WITH ALZHEIMER’S DEMENTIA IN US,  2020–2060 (MILLION)
                                TABLE 74 US FDA-APPROVED PRODUCTS, 2019–2022
                                TABLE 75 US: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 76 US: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 77 US: MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
           8.2.2 CANADA
                    8.2.2.1 Rising healthcare expenditure and increasing prevalence of chronic diseases to drive demand
                                TABLE 78 NEUROLOGICAL CONDITIONS PREVALENT IN CANADA, 2016–2031
                                TABLE 79 CANADA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 80 CANADA: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 81 CANADA: MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
           8.2.3 NORTH AMERICAN MARKET: RECESSION IMPACT
    8.3 EUROPE 
          TABLE 82 PREVALENCE OF DEMENTIA, BY COUNTRY, 2018 & 2050
          TABLE 83 EUROPE: NEUROMODULATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 84 EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 85 EUROPE: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 86 EUROPE: MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 87 EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 88 EUROPE: MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 89 EUROPE: MARKET FOR SACRAL NERVE STIMULATION MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 90 EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 91 EUROPE: MARKET FOR GASTRIC ELECTRICAL STIMULATION,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 92 EUROPE: MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 93 EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
           8.3.1 GERMANY
                    8.3.1.1 Increasing healthcare expenditure and presence of favorable reimbursement policies to drive market
                                TABLE 94 GERMANY: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 95 GERMANY: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 96 GERMANY: MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
           8.3.2 UK
                    8.3.2.1 Rising healthcare expenditure and high public- and private-sector investments to fuel market growth
                                TABLE 97 UK: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 98 UK: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 99 UK: MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
           8.3.3 FRANCE
                    8.3.3.1 Availability of insurance and favorable healthcare reforms to drive market
                                TABLE 100 FRANCE: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 101 FRANCE: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 102 FRANCE: MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
           8.3.4 ITALY
                    8.3.4.1 Easy access to healthcare services to create lucrative opportunities for market
                                TABLE 103 ITALY: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 104 ITALY: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 105 ITALY: MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
           8.3.5 SPAIN
                    8.3.5.1 Growing government-led initiatives related to healthcare to support market growth
                                TABLE 106 SPAIN: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 107 SPAIN: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 108 SPAIN: MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
           8.3.6 REST OF EUROPE
                    TABLE 109 REST OF EUROPE: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 110 REST OF EUROPE: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 111 REST OF EUROPE: MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
           8.3.7 EUROPEAN MARKET: RECESSION IMPACT
    8.4 ASIA PACIFIC 
          FIGURE 28 ASIA PACIFIC: NEUROMODULATION MARKET SNAPSHOT
          TABLE 112 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 113 ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 114 ASIA PACIFIC: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 115 ASIA PACIFIC: NEUROMODULATION MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 116 ASIA PACIFIC: MARKET FOR SPINAL CORD STIMULATION,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 117 ASIA PACIFIC: MARKET FOR DEEP BRAIN STIMULATION,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 118 ASIA PACIFIC: MARKET FOR SACRAL NERVE STIMULATION,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 119 ASIA PACIFIC: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 120 ASIA PACIFIC: MARKET FOR GASTRIC ELECTRICAL STIMULATION,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 121 ASIA PACIFIC: MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 122 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
           8.4.1 JAPAN
                    8.4.1.1 Increasing prevalence of neurological disorders to drive demand
                                TABLE 123 JAPAN: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 124 JAPAN: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 125 JAPAN: MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
           8.4.2 CHINA
                    8.4.2.1 Growing geriatric population to fuel demand
                                TABLE 126 CHINA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 127 CHINA: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 128 CHINA: MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
           8.4.3 INDIA
                    8.4.3.1 Improvements in healthcare infrastructure to contribute to market growth
                                TABLE 129 INDIA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 130 INDIA: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 131 INDIA: MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
           8.4.4 REST OF ASIA PACIFIC
                    TABLE 132 REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 133 REST OF ASIA PACIFIC: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 134 REST OF ASIA PACIFIC: MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
           8.4.5 ASIA PACIFIC MARKET: RECESSION IMPACT
    8.5 ROW 
          TABLE 135 ROW: NEUROMODULATION MARKET, BY COUNTRY/REGION, 2021–2028 (USD MILLION)
          TABLE 136 ROW: MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 137 ROW: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 138 ROW: MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 139 ROW: MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 140 ROW: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 141 ROW: MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 142 ROW: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 143 ROW: MARKET FOR GASTRIC ELECTRICAL STIMULATION,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 144 ROW: MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 145 ROW: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2021–2028 (USD MILLION)
           8.5.1 LATIN AMERICA
                    8.5.1.1 Increasing cases of depressive and post-traumatic stress disorders to drive demand
                                TABLE 146 LATIN AMERICA: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 147 LATIN AMERICA: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 148 LATIN AMERICA: MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
           8.5.2 MIDDLE EAST & AFRICA
                    8.5.2.1 Improvements in healthcare infrastructure and growing awareness regarding neuromodulation to drive market
                                TABLE 149 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY TYPE,  2021–2028 (USD MILLION)
                                TABLE 150 MIDDLE EAST & AFRICA: MARKET FOR INTERNAL,  BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 151 MIDDLE EAST & AFRICA: MARKET FOR EXTERNAL, BY TYPE,  2021–2028 (USD MILLION)
           8.5.3 GCC COUNTRIES
                    TABLE 152 GCC COUNTRIES: NEUROMODULATION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 153 GCC COUNTRIES: MARKET FOR INTERNAL, BY TYPE,  2021–2028 (USD MILLION)
                    TABLE 154 GCC COUNTRIES: EXTERNAL NEUROMODULATION MARKET, BY TYPE,  2021–2028 (USD MILLION)
           8.5.4 ROW MARKET: RECESSION IMPACT
9 COMPETITIVE LANDSCAPE (Page No. - 153)
    9.1 OVERVIEW 
    9.2 STRATEGIES ADOPTED BY KEY PLAYERS 
          TABLE 155 NEUROMODULATION MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
    9.3 REVENUE SHARE ANALYSIS, 2020–2022 
          FIGURE 29 NEUROMODULATION INDUSTRY: REVENUE ANALYSIS OF FIVE KEY PLAYERS, 2020–2022
    9.4 MARKET SHARE ANALYSIS, 2022 
          TABLE 156 NEUROMODULATION INDUSTRY: DEGREE OF COMPETITION
    9.5 COMPANY EVALUATION MATRIX, 2022 
           9.5.1 STARS
           9.5.2 EMERGING LEADERS
           9.5.3 PERVASIVE PLAYERS
           9.5.4 PARTICIPANTS
                    FIGURE 30 NEUROMODULATION INDUSTRY: COMPANY EVALUATION MATRIX, 2022
           9.5.5 COMPANY FOOTPRINT
                    TABLE 157 OVERALL COMPANY FOOTPRINT
                    TABLE 158 COMPANY REGION FOOTPRINT
                    TABLE 159 COMPANY TYPE FOOTPRINT
    9.6 START-UPS/SMALL AND MEDIUM-SIZED ENTERPRISES (SMES) EVALUATION MATRIX, 2022 
           9.6.1 PROGRESSIVE COMPANIES
           9.6.2 STARTING BLOCKS
           9.6.3 RESPONSIVE COMPANIES
           9.6.4 DYNAMIC COMPANIES
                    FIGURE 31 NEUROMODULATION INDUSTRY: START-UPS/SMES EVALUATION MATRIX, 2022
           9.6.5 COMPETITIVE BENCHMARKING
                    TABLE 160 NEUROMODULATION INDUSTRY: LIST OF KEY START-UPS/SMES
    9.7 COMPETITIVE SCENARIOS AND TRENDS 
           9.7.1 PRODUCT LAUNCHES & APPROVALS
                    TABLE 161 NEUROMODULATION INDUSTRY: PRODUCT LAUNCHES & APPROVALS, 2020–2023
           9.7.2 DEALS
                    TABLE 162 NEUROMODULATION INDUSTRY: DEALS, 2020–2023
10 COMPANY PROFILES (Page No. - 164)
(Business overview, Products/Services/Solutions offered, Recent Developments, MNM view)*
     10.1 KEY PLAYERS 
             10.1.1 MEDTRONIC PLC
                        TABLE 163 MEDTRONIC PLC: COMPANY OVERVIEW
                        FIGURE 32 MEDTRONIC PLC: COMPANY SNAPSHOT
                        TABLE 164 MEDTRONIC PLC: PRODUCT APPROVALS
                        TABLE 165 MEDTRONIC PLC: DEALS
             10.1.2 BOSTON SCIENTIFIC CORPORATION
                        TABLE 166 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
                        FIGURE 33 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
                        TABLE 167 BOSTON SCIENTIFIC CORPORATION: PRODUCT LAUNCHES AND APPROVALS
                        TABLE 168 BOSTON SCIENTIFIC CORPORATION: DEALS
             10.1.3 ABBOTT LABORATORIES
                        TABLE 169 ABBOTT LABORATORIES: COMPANY OVERVIEW
                        FIGURE 34 ABBOTT LABORATORIES: COMPANY SNAPSHOT
                        TABLE 170 ABBOTT LABORATORIES: PRODUCT LAUNCHES AND APPROVALS
             10.1.4 LIVANOVA PLC
                        TABLE 171 LIVANOVA PLC: COMPANY OVERVIEW
                        FIGURE 35 LIVANOVA PLC: COMPANY SNAPSHOT
                        TABLE 172 LIVANOVA PLC: PRODUCT APPROVALS
                        TABLE 173 LIVANOVA PLC: DEALS
             10.1.5 NEVRO CORPORATION
                        TABLE 174 NEVRO CORPORATION: COMPANY OVERVIEW
                        FIGURE 36 NEVRO CORPORATION: COMPANY SNAPSHOT
                        TABLE 175 NEVRO CORPORATION: PRODUCT APPROVALS
                        TABLE 176 NEVRO CORPORATION: DEALS
             10.1.6 NEUROSIGMA, INC.
                        TABLE 177 NEUROSIGMA, INC.: COMPANY OVERVIEW
                        TABLE 178 NEUROSIGMA, INC.: PRODUCT LAUNCHES & APPROVALS
                        TABLE 179 NEUROSIGMA, INC.: DEALS
                        TABLE 180 NEUROSIGMA, INC.: OTHERS
             10.1.7 NEUROPACE, INC.
                        TABLE 181 NEUROPACE, INC.: COMPANY OVERVIEW
                        FIGURE 37 NEUROPACE, INC.: COMPANY SNAPSHOT
                        TABLE 182 NEUROPACE, INC.: PRODUCT LAUNCHES & APPROVALS
                        TABLE 183 NEUROPACE, INC.: OTHERS
             10.1.8 SOTERIX MEDICAL INC.
                        TABLE 184 SOTERIX MEDICAL INC.: COMPANY OVERVIEW
                        TABLE 185 NEUROPACE, INC.: OTHERS
             10.1.9 SYNAPSE BIOMEDICAL INC.
                        TABLE 186 SYNAPSE BIOMEDICAL INC.: COMPANY OVERVIEW
             10.1.10 ALEVA NEUROTHERAPEUTICS SA
                        TABLE 187 ALEVA NEUROTHERAPEUTICS SA: COMPANY OVERVIEW
                        TABLE 188 ALEVA NEUROTHERAPEUTICS SA: PRODUCT APPROVALS
             10.1.11 THERANICA BIO-ELECTRONICS LTD.
                        TABLE 189 THERANICA BIO-ELECTRONICS LTD.: COMPANY OVERVIEW
                        TABLE 190 THERANICA BIO-ELECTRONICS LTD.: PRODUCT APPROVALS
             10.1.12 NEURONETICS
                        TABLE 191 NEURONETICS: COMPANY OVERVIEW
                        FIGURE 38 NEURONETICS: COMPANY SNAPSHOT
             10.1.13 AXONICS
                        TABLE 192 AXONICS: COMPANY OVERVIEW
                        FIGURE 39 AXONICS: COMPANY SNAPSHOT
                        TABLE 193 AXONICS: PRODUCT APPROVALS
                        TABLE 194 AXONICS: DEALS
             10.1.14 BIOINDUCTION
                        TABLE 195 BIOINDUCTION: COMPANY OVERVIEW
     10.2 OTHER PLAYERS 
             10.2.1 GIMER MEDICAL
             10.2.2 NALU MEDICAL INC.
             10.2.3 HELIUS MEDICAL TECHNOLOGIES
             10.2.4 MICROTRANSPONDER
             10.2.5 MAGSTIM
             10.2.6 ELECTROCORE, INC.
             10.2.7 RENISHAW PLC
             10.2.8 TVNS TECHNOLOGIES GMBH
             10.2.9 BIOWAVEGO USA
             10.2.10 BIOTRONIK
             10.2.11 SALUDA MEDICAL PTY LTD.
*Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
11 APPENDIX (Page No. - 202)
     11.1 DISCUSSION GUIDE 
     11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     11.3 CUSTOMIZATION OPTIONS 
     11.4 RELATED REPORTS 
     11.5 AUTHOR DETAILS